Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 5 minute read Pharma Industry News Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline. byPallavi MadhirajuMay 23, 2025